To study the effect of TLR9 activation on hepatic fibrosis model; CpG (TLR9 agonists, 20 μg/mouse) were administered by a hydrodynamic transfection manner into fibrotic mice model receiving the CCl4 injections as described in materials and methods. Here, TLR9 is linked to Hepatic fibrosis.